Home / Business and Economy / Pharma Warns of Drug Delays Over Funding Fears
Pharma Warns of Drug Delays Over Funding Fears
22 Sep
Summary
- European drugmakers may delay new medications due to funding concerns.
- Companies warn of reduced investment if governments don't increase funding.
- Competition from China and the US is a major factor in the warnings.
European pharmaceutical companies are escalating their efforts to secure increased investment from financially strained regional governments. These drugmakers have been vocal for months, cautioning that they may be forced to curtail investments and postpone the introduction of novel medications.
The core of their concern lies in the risk of falling behind international competitors, specifically China and the United States. The companies are emphasizing that a failure by European governments to prioritize funding for new medicines could have significant long-term consequences for the region's healthcare innovation.
This concerted push highlights a critical juncture for the pharmaceutical sector in Europe, as it navigates economic challenges while striving to maintain its research and development capabilities.
